Calendar

pharmadog

Week of Oct 13, 2025

Oct 15, 2025approval318d agoLACOSAMIDE — FDA approvalLACOSAMIDE

Sponsor: HETERO LABS LTD V. Form: TABLET. Route: ORAL

full page →LACOSAMIDE →fda approvals ↗

Oct 15, 2025approval318d agoCONJUGATED ESTROGENS (ESTROGENS, CONJUGATED) — FDA approvalIngenus Pharmaceuticals LLC

Sponsor: NOVAST LABS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 15, 2025approval318d agoCONJUGATED ESTROGENS (ESTROGENS, CONJUGATED) — FDA approvalIngenus Pharmaceuticals LLC

Sponsor: NOVAST LABS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 15, 2025approval318d ago— FDA approvalMerck Sharp & Dohme LLC

Sponsor: MERCK SHARP AND DOHME LLC

full page →fda approvals ↗

Oct 15, 2025approval318d agoLYTGOBI (FUTIBATINIB) — FDA approvalfutibatinib

Sponsor: TAIHO ONCOLOGY. Form: TABLET. Route: ORAL

full page →futibatinib →fda approvals ↗

Oct 15, 2025approval318d agoPANTOPRAZOLE SODIUM — FDA approvalPANTOPRAZOLE SODIUM

Sponsor: ASPIRO. Form: INJECTABLE. Route: INTRAVENOUS

full page →PANTOPRAZOLE SODIUM →fda approvals ↗

Oct 15, 2025approval318d agoPANTOPRAZOLE SODIUM — FDA approvalPANTOPRAZOLE SODIUM

Sponsor: ASPIRO. Form: INJECTABLE. Route: INTRAVENOUS

full page →PANTOPRAZOLE SODIUM →fda approvals ↗

Oct 15, 2025approval318d agoAMLODIPINE BESYLATE AND VALSARTAN (AMLODIPINE BESYLATE) — FDA approvalamlodipine besylate

Sponsor: TORRENT. Form: TABLET. Route: ORAL

full page →amlodipine besylate →fda approvals ↗

Oct 15, 2025approval318d agoAMLODIPINE BESYLATE AND VALSARTAN (AMLODIPINE BESYLATE) — FDA approvalamlodipine besylate

Sponsor: TORRENT. Form: TABLET. Route: ORAL

full page →amlodipine besylate →fda approvals ↗

Oct 15, 2025approval318d agoLIRAGLUTIDE — FDA approvalNovo Nordisk Inc

Sponsor: NANJING KING FRIEND. Form: SOLUTION. Route: SUBCUTANEOUS

full page →fda approvals ↗

Oct 16, 2025approval317d agoXELJANZ (TOFACITINIB CITRATE) — FDA approvalBiocon Pharma Ltd

Sponsor: PF PRISM CV. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 16, 2025approval317d agoXELJANZ (TOFACITINIB CITRATE) — FDA approvaltofacitinib citrate ER

Sponsor: PFIZER. Form: SOLUTION. Route: ORAL

full page →tofacitinib citrate ER →fda approvals ↗

Oct 16, 2025approval317d agoSIMLANDI (ADALIMUMAB-RYVK) — FDA approvalAlvotech

Sponsor: ALVOTECH USA INC. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 16, 2025approval317d agoYORVIPATH (PALOPEGTERIPARATIDE) — FDA approvalpalopegteriparatide

Sponsor: ASCENDIS PHARMA BONE. Form: SOLUTION. Route: SUBCUTANEOUS

full page →palopegteriparatide →fda approvals ↗

Oct 16, 2025approval317d agoALLOPURINOL — FDA approvalMylan Pharmaceuticals Inc

Sponsor: REGCON HOLDINGS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 16, 2025approval317d agoAMJEVITA (ADALIMUMAB-ATTO) — FDA approvalAMJEVITA

Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

full page →AMJEVITA →fda approvals ↗

Oct 16, 2025approval317d agoTRIMETHOBENZAMIDE HYDROCHLORIDE — FDA approvalGavis Pharmaceuticals LLC

Sponsor: BPI LABS. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 16, 2025approval317d agoCYLTEZO (ADALIMUMAB-ADBM) — FDA approvalCYLTEZO

Sponsor: BOEHRINGER INGELHEIM. Form: INJECTABLE. Route: INJECTION

full page →CYLTEZO →fda approvals ↗

Oct 16, 2025approval317d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

full page →HYRIMOZ →fda approvals ↗

Oct 16, 2025approval317d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

full page →ganaxolone →fda approvals ↗

Oct 16, 2025approval317d agoZTALMY (GANAXOLONE) — FDA approvalganaxolone

Sponsor: IMMEDICA PHARMA. Form: SUSPENSION. Route: ORAL

full page →ganaxolone →fda approvals ↗

Oct 16, 2025approval317d agoFERABRIGHT (FERUMOXYTOL) — FDA approvalCovis Pharma BV

Sponsor: COVIS. Form: SOLUTION. Route: INTRAVENOUS

full page →fda approvals ↗

Oct 16, 2025approval317d agoSOJOURN (SEVOFLURANE) — FDA approvalSEVOFLURANE

Sponsor: PIRAMAL CRITICAL. Form: LIQUID. Route: INHALATION

full page →SEVOFLURANE →fda approvals ↗

Oct 16, 2025approval317d agoYUFLYMA (ADALIMUMAB-AATY) — FDA approvalYUFLYMA

Sponsor: CELLTRION. Form: INJECTABLE. Route: INJECTION

full page →YUFLYMA →fda approvals ↗

Oct 17, 2025approval316d agoVYVGART HYTRULO (EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC) — FDA approvalARGENX SE

Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 17, 2025approval316d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval316d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval316d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

Sponsor: NOVO. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval316d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalAmneal Pharmaceuticals, Inc.

Sponsor: IMPAX LABS. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Oct 17, 2025approval316d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

full page →obinutuzumab →fda approvals ↗

Oct 17, 2025approval316d agoGAZYVA (OBINUTUZUMAB) — FDA approvalobinutuzumab

Sponsor: GENENTECH. Form: INJECTABLE. Route: INJECTION

full page →obinutuzumab →fda approvals ↗

Oct 17, 2025approval316d agoBALVERSA (ERDAFITINIB) — FDA approvalerdafitinib

Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

full page →erdafitinib →fda approvals ↗

Oct 17, 2025approval316d agoTEZSPIRE (TEZEPELUMAB-EKKO) — FDA approvaltezepelumab

Sponsor: ASTRAZENECA AB. Form: SOLUTION. Route: SUBCUTANEOUS

full page →tezepelumab →fda approvals ↗

Oct 17, 2025approval316d agoHADLIMA (ADALIMUMAB-BWWD) — FDA approvalHADLIMA

Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

full page →HADLIMA →fda approvals ↗

Oct 17, 2025approval316d agoCLOMIPHENE CITRATE — FDA approvalCLOMIPHENE CITRATE

Sponsor: NOVITIUM PHARMA. Form: TABLET. Route: ORAL

full page →CLOMIPHENE CITRATE →fda approvals ↗

Oct 17, 2025approval316d agoTRIAMCINOLONE ACETONIDE — FDA approvaltriamcinolone acetonide Rising

Sponsor: ALEMBIC. Form: INJECTABLE. Route: INJECTION

full page →triamcinolone acetonide Rising →fda approvals ↗

Oct 17, 2025approval316d agoBUCAPSOL (BUSPIRONE HYDROCHLORIDE) — FDA approvalBUSPIRONE HYDROCHLORIDE

Sponsor: EPIC PHARMA LLC. Form: CAPSULE. Route: ORAL

full page →BUSPIRONE HYDROCHLORIDE →fda approvals ↗

Oct 17, 2025approval316d agoEPIOXA HD/EPIOXA KIT (RIBOFLAVIN 5'-PHOSPHATE SODIUM) — FDA approvalriboflavin 5'-phosphate sodium

Sponsor: GLAUKOS. Form: SOLUTION/DROPS. Route: OPHTHALMIC

full page →riboflavin 5'-phosphate sodium →fda approvals ↗

Oct 17, 2025approval316d agoPOMALIDOMIDE — FDA approvalPOMALIDOMIDE

Sponsor: MYLAN. Form: CAPSULE. Route: ORAL

full page →POMALIDOMIDE →fda approvals ↗

Oct 17, 2025approval316d agoVYVGART (EFGARTIGIMOD ALFA) — FDA approvalARGENX SE

Sponsor: ARGENX BV. Form: INJECTABLE. Route: INJECTION

full page →fda approvals ↗

Oct 17, 2025approval316d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval316d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval316d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Oct 17, 2025approval316d agoTACROLIMUS — FDA approvaltacrolimus ER

Sponsor: GLENMARK PHARMS LTD. Form: CAPSULE. Route: ORAL

full page →tacrolimus ER →fda approvals ↗

Week of Oct 20, 2025

Oct 20, 2025approval313d agoBEYFORTUS (NIRSEVIMAB-ALIP) — FDA approvalnirsevimab

Sponsor: ASTRAZENECA AB. Form: INJECTABLE. Route: INJECTION

full page →nirsevimab →fda approvals ↗

Oct 20, 2025approval

← prev

page 336 of 380

Week of Oct 13, 2025

Week of Oct 20, 2025